LXEO Lexeo Therapeutics, Inc.: institutional ownership and insider trading
150 funds reported holding $479M of Lexeo Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $43.7M, with 26 new positions and 21 funds selling out; over the last 12 months insiders bought $0 and sold $752K on the open market.
Famous investors holding LXEO
- Ken Griffin (Citadel Advisors): $18.1M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $13.2M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $1.17M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $92.5K, 0.0% of the portfolio
Largest institutional holders of LXEO
- VANGUARD GROUP INC — $38.7M
- SUVRETTA CAPITAL MANAGEMENT, LLC — $29.7M
- JANUS HENDERSON GROUP PLC (JHG) — $28.5M
- Affinity Asset Advisors, LLC — $27.0M
- BlackRock, Inc. (BLK) — $26.7M
- RA CAPITAL MANAGEMENT, L.P. — $23.3M
- Frazier Life Sciences Management, L.P. — $22.5M
- STATE STREET CORP (STT, STT-PG) — $20.3M
- Vestal Point Capital, LP — $20.1M
- Paradigm Biocapital Advisors LP — $19.4M
Recent LXEO insider trades
- Aug 18, 2026: Townsend Richard Nolan sold 3,345 shares ($16.6K)
- Aug 18, 2026: Otero Jose Manuel sold 1,304 shares ($6.47K)
- Aug 18, 2026: Tamayo Louis Edward sold 4,117 shares ($20.2K)
- Jul 1, 2026: Townsend Richard Nolan sold 25,947 shares ($116K)
5%+ owners
- BALYASNY ASSET MANAGEMENT L.P.: 10.0% (Schedule 13G/A, filed Aug 14, 2026)
- Affinity Asset Advisors, LLC: 8.4% (Schedule 13G/A, filed Aug 13, 2026)
- SUVRETTA CAPITAL MANAGEMENT, LLC: 7.7% (Schedule 13G, filed Apr 13, 2026)
- STATE STREET CORPORATION: 5.5% (Schedule 13G, filed Aug 7, 2026)
- JPMORGAN CHASE & CO.: 5.5% (Schedule 13G, filed Oct 13, 2026)
- Paradigm BioCapital Advisors LP: 5.3% (Schedule 13G/A, filed Aug 14, 2026)